论文部分内容阅读
目的探讨氯沙坦与缬沙坦治疗高血压合并高尿酸血症临床效果的对比观察。方法选取2015年3月—2016年8月深圳市宝安医院集团第二人民医院68例高血压合并高尿酸血症患者作为研究对象,随机分为对照组与观察组,每组34例。对照组予以缬沙坦治疗,观察组使用氯沙坦治疗。对比两组治疗前、治疗1个月、治疗2个月后血压(收缩压和舒张压)情况、血尿酸水平及生活质量。结果两组治疗后收缩压及舒张压均有所下降,两组比较差异无统计学意义(P>0.05);两组治疗前血尿酸水平对比不明显(P>0.05);治疗1个月、2个月后,观察组血尿酸数据分别为(320.20±5.59)μmol/L、(287.94±4.97)μmol/,明显低于对照组(P<0.05);治疗后,观察组生活质量表评分为(86.18±3.21)分,明显优于对照组(P<0.05)分。结论氯沙坦与缬沙坦应用于高血压合并高尿酸血症患者中,均可有效降低血压,但氯沙坦在控制血尿酸方面效果更佳。
Objective To investigate the clinical effects of losartan and valsartan in the treatment of hypertension combined with hyperuricemia. Methods From March 2015 to August 2016, 68 patients with hypertension complicated with hyperuricemia in Shenzhen Baoan Hospital Group Second People’s Hospital were randomly divided into control group and observation group with 34 cases in each group. The control group was treated with valsartan, and the observation group was treated with losartan. Blood pressure (systolic and diastolic blood pressure), serum uric acid level and quality of life were compared between two groups before treatment, one month after treatment and two months after treatment. Results After treatment, the systolic and diastolic blood pressure decreased in both groups, with no significant difference between the two groups (P> 0.05). The levels of serum uric acid in the two groups before treatment were not significantly different (P> 0.05) After 2 months, the data of blood uric acid in the observation group were (320.20 ± 5.59) μmol / L and (287.94 ± 4.97) μmol / L respectively, which were significantly lower than those in the control group (P <0.05) (86.18 ± 3.21) points, which was significantly better than that of the control group (P0.05). Conclusion Losartan and valsartan can effectively reduce blood pressure in hypertensive patients with hyperuricemia, but losartan is more effective in controlling uric acid and uric acid.